Meeting
2013 ASCO Annual Meeting
Randomized phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations.
Authors
Leena Gandhi
Dana-Farber Cancer Institute, Boston, MA
Leena Gandhi , Jean-Charles Soria , Richard Bryce , Benjamin Besse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
2012-004743-68
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS8124)
DOI
10.1200/jco.2013.31.15_suppl.tps8124
Abstract #
TPS8124
Poster Bd #
42H
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2018 ASCO Annual Meeting
Upfront next generation sequencing in NSCLC: A publicly funded perspective.
First Author: Kirstin Perdrizet
Poster
2014 ASCO Annual Meeting
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
First Author: Geoffrey R. Oxnard